Aquestive Therapeutics Inc. Revenue 2017–2025
Aquestive Therapeutics Inc. annual/quarterly revenue history and growth rate from 2017 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Aquestive Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 14.4 M, a 65.67% increase year-over-year.
- Aquestive Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 46.0 M, a 21.67% decrease year-over-year.
- Aquestive Therapeutics Inc. annual revenue for 2025 was 44.5 M, a 22.61% decrease from 2024.
- Aquestive Therapeutics Inc. annual revenue for 2024 was 57.6 M, a 13.80% increase from 2023.
- Aquestive Therapeutics Inc. annual revenue for 2023 was 50.6 M, a 6.09% increase from 2022.
- Aquestive Therapeutics Inc. annual revenue for 2022 was 47.7 M.
Aquestive Therapeutics Inc. (AQST) — Frequently Asked Questions
Aquestive Therapeutics Inc. (AQST) is a publicly traded US company. It has a market capitalization of $442M. In fiscal 2025 it reported revenue of $45M and net income of -$84M. Explore AQST's stock price, financial statements, earnings history, margins and key ratios below.
What is Aquestive Therapeutics Inc.'s market cap?
Aquestive Therapeutics Inc. (AQST) has a market capitalization of $442M.
What is the AQST stock price?
AQST trades at $4.13 (+3.63% on the day).
How much revenue does Aquestive Therapeutics Inc. make?
Aquestive Therapeutics Inc. reported revenue of $45M in fiscal 2025.
Is AQST profitable?
In fiscal 2025, Aquestive Therapeutics Inc. reported net income of -$84M.